Dr Varun Mehra

Dr Varun Mehra is a leading Consultant Haematologist based in London who specialises in myelodysplastic syndrome, acute leukaemia, bone marrow failure, autologous transplantation for autoimmune conditions such as multiple sclerosis, Crohn's disease, systemic sclerosis, etc, allogeneic stem cell transplantation, immunotherapy and post-transplant complications. Dr Mehra completed his post-graduate specialist Haematology training at world renowned Kings College Hospital, London, where he has been working for past few years as a core member of a busy Stem Cell Transplant & Cellular therapy unit, while pursuing his MD (res) Degree with Kings College London University in developing novel diagnostic biomarkers for invasive fungal disease (aspergillosis) in immunocompromised Haemato-oncology patients. Dr Mehra has a strong track record for his involvement in Clinical Trials, more recently as Lead Chief Investigator and Principal Investigator of various infection and transplant related ATMP and Non-ATMP Clinical Trials in the UK. He has regularly presented in key regional, national and international meetings as invited Speaker as well as Faculty member in field of Mycology and Stem Cell Transplantation. He is an active Member of EBMT Autoimmune and Infectious disease working party and Member of EORTC advisory group on Infections and Leukaemia. Dr Mehra's main research interests are in infections of immunocompromised hosts, graft versus host disease, transplantation of autoimmune diseases including cellular therapy strategies; and have helped develop exciting collaborations in Infection research & education within and outside Kings Health Partners with bench to bed translation opportunities. He has published regularly on his disease specific research interests in high impact clinical and scientific journals. He has been active in developing educational pathways and trainee mentorship programmes within haemato-pathology training in London. He previously chaired London School of Pathology Specialist Trainee Committee and represented London Pathology Trainees in the Royal College Specialist Advisory group between 2014-2016. He is currently the Education Lead for King’s Haematolog Training program. He currently sits on the KHP Institute of Haematology Education & Training steering group, playing an active role in developing post-graduation modules for training in clinical haematology and other disease specific Preceptorship training programs. Dr Mehra is also fully trained in the assessment of patients for, and delivery of CAR-T therapy, a highly specialised new therapy that has recently been licensed for certain patients with relapsed high grade B cell lymphomas and acute lymphoblastic leukaemia.